Search results:
General Information
| Gene_Symbol | Gene_ID | Gene_Name | Chromosome | Alias |
|---|---|---|---|---|
| PTEN | 5728 | Phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 10 | BZS; DEC; CWS1; GLM2; MHAM; TEP1; MMAC1; PTEN1; 10q23del |
- Evidence
- Gene
- mRNA
- CDS
- Protein
- PTM
- Enzyme
- PPi
- Pathway
- Structural
- Domain
- Ontology
- SNP
- Drug
- External Links
Evidence Information
| Pubmed ID | Year | Sample Information | Techniques | Mechanism | Fold Change | Remark |
|---|---|---|---|---|---|---|
| 22610356 | 2011 | Cell line : - Source : - Sample Type : CRC tumor and normal tissue No. of Sample : 852 CRC patients Stage : TNM Stage I-III | Meta analysis | Down-regulation | - | Loss of expression of PTEN is a potential biomarker for resistance to anti-EGFR monoclonal therapy, particularly in mCRC patients with KRAS wild type. |
| 22848291 | 2011 | Cell line : - Source : Department of Gastroenterology, the First Affiliated Hospital of Soochow University and the National Engineering Center for Biochip in Shanghai, China. Sample Type : CRC tumor and normal tissue No. of Sample : 139 CRC, 18 adenomatous polyps and 50 paired paracancerous benign mucosas Stage : TNM Stage I-Iv | Immunohistochemistry | Down-regulation | - | PTEN may have potential as a prognostic marker in human CRC. CRCs with a low expression or deletion of PTEN may progress towards invasion and even metastasis. |
| 22944341 | 2012 | Cell line : - Source : - Sample Type : CRC tumor and normal tissue No. of Sample : 32 colorectal cancer tissue samples 48 and normal rectal tissue samples 23 Stage : TNM Stage I-IV | Immunohistochemistry | Down-regulation | - | Reduced PTEN expression and MMP-7 over-expression may play important roles in the pathogenesis of colorectal cancer. Combined detection may provide prognostic benefit towards colorectal cancer. |
| 22990545 | 2012 | Cell line : - Source : Surgical Department of Dr Alexandru Gafencu Emergency Military Hospital, Constanta, Romania. Sample Type : - No. of Sample : 22 colorectal cancer resection specimens Stage : TNM Stage III,IV | Immunohistochemistry | Down-regulation | - | The incidence of the mutational inactivation of PTEN in colorectal cancer was very low; negative or weakly expressed PTEN tumors had a tendency to be diagnosed in advanced stages. |
| 23170117 | 2012 | Cell line : - Source : - Sample Type : Case control study No. of Sample : 68 cases of colorectal cancer Stage : - | Immunohistochemistry, Kaplan-Meier survival analysis. | Down-regulation | - | PTEN, STAT3 and VEGF-C expression are beneficial prognostic factors, which may aid in the accurate assessment of prognosis and guide clinical treatment of colorectal cancer patients. |
| 23174819 | 2012 | Cell line : - Source : - Sample Type : - No. of Sample : 30 CRC samples and five CRC cell lines Stage : - | - | Down-regulation | - | MiR-21 targets PTEN at the post-transcriptional level and regulates cell proliferation and invasion in CRC. It may serve as a novel therapeutic target in CRC. The PTEN protein levels in CRC tissues and cells had an inverse correlation with miR-21 expression. miR-21 was overexpressed in CRC compared with adenomas and normal tissues. |
| 22610356 | 2012 | Cell line : - Source : Utah, the Northern California Kaiser Permanente Medical Care Program (KPMCP) and the Twin Cities Metropolitan area of Minnesota. Sample Type : Case control study No. of Sample : 871 male and 685 female colon cancer cases and 1047 male and 909 female controls Stage : - | Meta-analysis | Down-regulation | - | Loss of expression of PTEN is a potential biomarker for resistance to anti-EGFR monoclonal therapy, particularly in mCRC patients with KRAS wild type. |
| 23465274 | 2013 | Cell line : - Source : Turkish population. Sample Type : Case control study No. of Sample : 203 patients with CRC (127 colon, 76 rectum) and 245 healthy controls Stage : - | Tissue microarray,FISH | Mutation | - | Genomic PTEN gene alterations caused by deletion or gene disruption characterize a fraction of rectal cancers with particularly poor outcome |
| 20622004 | 2010 | Cell line : - Source : - Sample Type : - No. of Sample : 852 CRC patients Stage : - | - | Polymorhpism | - | Variation at 9 tagSNPs occures.
|
| 23062208 | 2012 | Cell line : - Source : - Sample Type : - No. of Sample : 404 CRC patients Stage : - | PCR-RFLP | Polymorhpism | - | The (-/-) genotype of PTEN IVS4 gene might be associated with increased risk for development of CRC. |
Gene Details
| Gene Type | protein coding |
|---|---|
| Gene Family | Protein tyrosine phosphatases / Class I Cys-based PTPs : PTENs |
| Description | This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. [provided by RefSeq, Jul 2008] |
| Chromosome | 10 |
| Location | 10q23.3 |
| Start | 87863438 |
| End | 87971930 |
| Strand | + |
| Gene Sequence | Download Select all |
| Length | 108493 |
| OMIM ID | 601728 |
| HGNC ID | HGNC:9588 |
| Unigene ID | Hs.500466 |
| Ensembl ID | ENSG00000171862 |
| PharmGKB ID | PA33942 |
mRNA Information
| mRNA ID | NM_000314.5 |
|---|---|
| Exon | join(1..1111,30588..30672,62076..62120,67609..67652, 69576..69814,88681..88822,94416..94582,97457..97681, 101850..108493) | mRNA Sequence | Download Select all |
| Length | 5572 |
CDS Information
| Location | join(1033..1111,30588..30672,62076..62120,67609..67652, 69576..69814,88681..88822,94416..94582,97457..97681, 101850..102035) |
|---|---|
| CDS Sequence | Download Select all |
| CCDS ID | CCDS31238.1 |
Protein Information
| Protein ID | NP_000305.3 |
|---|---|
| Protein Name | Phosphatase and tensin homolog (mutated in multiple advanced cancers 1) |
| Molecular Wt. (Da) | 47035 |
| Protein Sequence | Download Select all |
| Length | 403 |
| Uniprot ID | P55060 |
| Ensembl Protein ID | ENSP00000262982 |
Post-translational Modification Information (Source : HPRD)
| Residue | Type | site |
|---|---|---|
| Y | Phosphorylation | 240 |
| Y | Phosphorylation | 315 |
| T | Phosphorylation | 382 |
| T | Phosphorylation | 383 |
| S | Phosphorylation | 370 |
| T | Phosphorylation | 366 |
| T | Phosphorylation | 366 |
| S | Phosphorylation | 370 |
| S | Phosphorylation | 380 |
| S | Phosphorylation | 385 |
| S | Phosphorylation | 385 |
| K | Acetylation | 6 |
Enzyme Information
| EC | 3.1.3.48 |
|---|---|
| Name | protein-tyrosine-phosphatase phosphotyrosine phosphatase phosphoprotein phosphatase (phosphotyrosine) phosphotyrosine histone phosphatase protein phosphotyrosine phosphatase tyrosylprotein phosphatase phosphotyrosine protein phosphatase phosphotyrosylprotein phosphatase tyrosine O-phosphate phosphatase PPT-phosphatase PTPase [phosphotyrosine]protein phosphatase PTP-phosphatase |
| Class | Hydrolases; Acting on ester bonds; Phosphoric-monoester hydrolases |
| Sysname | protein-tyrosine-phosphate phosphohydrolase |
| Substrate | protein tyrosine phosphate [CPD:C01167]; H2O |
| Product | protein tyrosine [CPD:C00585]; phosphate |
| Reaction (IUBMB) |  |
PPi Information
(Click to view network : Source STRING) View
| Interactant Gene ID (Source: HPRD) | Gene Symbol | HPRD ID | Ref Seq ID | Technique | References |
|---|---|---|---|---|---|
| 857 | CAV1 | 3028 | NP_001744.2 | in vivo | 12176037 |
| 6794 | STK11 | 3740 | NP_000446.1 | in vitro;in vivo;yeast 2-hybrid | 15987703 |
| 7157 | TP53 | 1859 | NP_000537.3 | in vitro;in vivo | 12620407 |
| 9351 | SLC9A3R2 | 5946 | NP_001123484.1 | in vivo | 16456542 |
| 9368 | SLC9A3R1 | 5406 | NP_004243.1 | in vitro | 16456542 |
| 10813 | UTP14A | 6712 | NP_006640.2 | yeast 2-hybrid | 16169070 |
| 10980 | COPS6 | 16735 | NP_006824.2 | yeast 2-hybrid | 16169070 |
| 22983 | MAST1 | 17469 | NP_055790.1 | in vitro;yeast 2-hybrid | 15951562 |
| 23139 | MAST2 | 11294 | NP_055927.2 | in vitro;yeast 2-hybrid | 15951562 |
Pathway Information
| Pathway Name | Pathway ID |
|---|---|
| Central carbon metabolism in cancer | hsa05230 |
| Endometrial cancer | hsa05213 |
| Focal adhesion | hsa04510 |
| FoxO signaling pathway | hsa04068 |
| Glioma | hsa05214 |
| Hepatitis B | hsa05161 |
| Inositol phosphate metabolism | hsa00562 |
| Insulin resistance | hsa04931 |
| Melanoma | hsa05218 |
| MicroRNAs in cancer | hsa05206 |
| mTOR signaling pathway | hsa04150 |
| p53 signaling pathway | hsa04115 |
| Pathways in cancer | hsa05200 |
| Phosphatidylinositol signaling system | hsa04070 |
| PI3K-Akt signaling pathway | hsa04151 |
| Prostate cancer | hsa05215 |
| Small cell lung cancer | hsa05222 |
| Sphingolipid signaling pathway | hsa04071 |
| Tight junction | hsa04530 |
Structure Information
| PDB ID | 1D5R |
|---|---|
| Resolution | 2.1 |
| Method | X-RAY DIFFRACTION |
| Chains | A |
| Molecule | PHOSPHOINOSITIDE PHOSPHATASE PTEN |
| Model | View |
Domain Information
| ID | Location | Description |
|---|---|---|
| pfam10409 | 188-349 | PTEN_C2 |
| cl11068 | 188-349 | PTEN_C2 superfamily |
| smart00404 | 92-183 | PTPc_motif |
| cl21483 | 92-183 | PTPc superfamily |
| smart00012 | 92-183 | PTPc_DSPc |
| PTZ00242 | 47-163 | PTZ00242 |
| smart00195 | 87-159 | DSPc |
| pfam00782 | 103-159 | DSPc |
| cd00047 | 37-160 | PTPc |
| COG2453 | 87-184 | CDC14 |
| PRK12361 | 89-159 | PRK12361 |
| smart00194 | 54-176 | PTPc |
| pfam00102 | 92-176 | Y_phosphatase |
Ontology Information
| HPRD ID | 737 |
|---|---|
| Molecular Class | Lipid phosphatase |
| Molecular Function | Transmembrane receptor activity (GO:0004888) |
| Biological Process | Cell communication (GO:0007154); Signal transduction (GO:0007165) |
Drug Information
No matching records could be found.